Biological Assembly 1  

 3D View: Structure | 1D-3D View | Validation Report

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 39.80 kDa 
• Atom Count: 2716 
• Modelled Residue Count: 298 
• Deposited Residue Count: 344 
• Unique protein chains: 1

1RJB

Crystal Structure of FLT3

• PDB DOI: 10.2210/pdb1RJB/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Trichoplusia ni
• Mutation(s): No 


• Deposited: 2003-11-19 Released: 2004-02-03 
• Deposition Author(s): Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., Saxena, K.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.248 
• R-Value Work: 0.210 
• R-Value Observed: 0.220 

Literature

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., Saxena, K.

(2004) Mol Cell 13: 169-178

• PubMed: 14759363 
• DOI: 10.1016/s1097-2765(03)00505-7
• Primary Citation of Related Structures:  
  1RJB


• PubMed Abstract: 
  

FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis. Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant numbers of patients with acute myelogenous leukemia (AML). The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain. To further understand the nature of FLT3 autoinhibition and regulation, we have determined the crystal structure of the autoinhibited form of FLT3. This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases. The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.

---

Organizational Affiliation: 

Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
FL cytokine receptor	A	344	Homo sapiens	Mutation(s): 0  Gene Names: FLT3, CD135, FLK2, STK1 EC: 2.7.1.112 (PDB Primary Data), 2.7.10.1 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P36888 (Homo sapiens) Explore P36888  Go to UniProtKB:  P36888
PHAROS:  P36888 GTEx:  ENSG00000122025

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.248 
• R-Value Work: 0.210 
• R-Value Observed: 0.220 
• Space Group: P 4₃ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 80.651	α = 90
b = 80.651	β = 90
c = 150.12	γ = 90

Software Package:

Software Name	Purpose
CNX	refinement
HKL-2000	data reduction
CrystalClear	data scaling
AMoRE	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2003-11-19 
• Released Date: 2004-02-03 
Deposition Author(s): Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., Saxena, K.

Revision History  

• Version 1.0: 2004-02-03
  Type: Initial release
  
• Version 1.1: 2008-04-29
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance